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According to The World Health Organization, acinic cell carcinoma (ACC) is a malignant epi-thelial neoplasm of the salivary glands in which 
at least some of the neoplastic cells demonstrate serous 
acinar cell differentiation characterized by cytoplasmic 
zymogen secretory granules. Salivary ductal cells can 
also be a component of this low-grade neoplasm that 
most often occurs in the parotid gland and presents at a 
relatively younger age than other salivary gland tumors. 
This malignant disease shows a female predilection.1
ACC was referred to as an entity for the first time 
more than 50 years ago by Godwin et al.2 The terms 
“acinar” and “serous” refer to the histologic resem-
blance of tumor cells to the secretory parenchymatous 
cells of the parotid, grouped in grape-like clusters and 
hence given the latin name “acinus” (Figure 1). In the 
past, the malignant nature of this cancer had been 
disputed or gone unrecognized. In earlier literature, it 
was classified as an “acinic cell tumor” or benign “ad-
enoma”. Recent literature detailing the high potential 
for recurrence, metastases and even death resulted in 
WHO re-classification as a “malignant carcinoma”, 
though with a more common low-grade behavior.3
Epidemiology
Salivary gland cancers comprise about 0.6% of all can-
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acinic cell carcinoma (acc) is a low-grade malignant salivary neoplasm that constitutes approximately 
17% of primary salivary gland malignancies. in the head and neck region, the parotid gland is the pre-
dominant site of origin and women are usually more frequently diagnosed than men. previous radiation 
exposure and familial predisposition are some of the risk factors for acc. a slowly enlarging mass lesion 
in the tail of the parotid gland is the most frequent presentation. the diagnosis is usually confirmed with 
a fine needle aspiration biopsy, and surgical excision is the main treatment of this malignant neoplasm. 
other treatment modalities such as radiotherapy may be indicated in some cases. acc has a significant 
tendency to recur, to produce metastases (cervical lymph nodes and lungs), and may have an aggressive 
evolution. therefore, long-term follow-up is mandatory after treatment. 
cers. ACCs constitute approximately 6% to 8% of all 
salivary gland neoplasms, and 17% of primary salivary 
gland malignancies, representing the third most com-
mon epithelial malignancy of the salivary glands in 
adults, following mucoepidermoid carcinoma and ade-
noid cystic carcinoma. In the pediatric age group, ACC 
is the second most common epithelial malignancy fol-
lowing mucoepidermoid carcinoma.
Women are more frequently diagnosed (58.8%) 
than men (41.2%).4,5 The median age at diagnosis is 
52 years, younger than for most other salivary gland 
cancers. Slightly more than 16% of patients were un-
der the age of 30 and women comprise a significantly 
larger proportion of cases in this younger age group 
(64.4%) than among those 30 years of age or older.4,5
 According to the National Cancer Data Base 
Report on cancer of the head and neck in the United 
States, the parotid gland was the predominant site 
of origin (86.3%) for reported ACCs.4 The median 
tumor size was 2 centimeters and slightly more than 
two-thirds of cases presented for treatment during 
the first stage of the disease. Regional and distant 
metastasis, high grade, and large tumor size were 
all more common among patients older than 30. No 
ethnic or racial predilection showed an association 
with ACC.4, 5
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Localization
Between 81% and 98% of ACCs of the salivary glands 
occur in the parotid, 11% in the submandibular gland, 
and 3% to 12% in the minor salivary glands, most com-
monly in the palate.6 Less than 1% of ACC arise in the 
sublingual gland. In addition to major salivary glands, 
ACC of the head and neck region was reported to oc-
cur in the minor salivary glands,7 oral cavity,8 lips,9 pal-
ate,10 larynx,11 mandible,12 nose13 and paranasal sinuses.14 
Other sites of origin of ACC in the human body include 
the pancreas,15 stomach,16 lung,17 breast,18 and prostate.19
Risk factors
Possible causes of ACC include previous radiation ex-
posure20 and familial predisposition.21, 22 Women are 
more apt to get this malignant neoplasm.4,5 The authors 
of this article recently noticed a chronological associa-
tion between onset and recurrence of ACC and preg-
nancy, in one case.  
Long-term follow-up studies of the survivors of the 
atomic bomb explosions in Hiroshima and Nagasaki 
show an increased relative risk of 3.5 for benign and 
11 for malignant salivary neoplasms. Therapeutic ra-
diation, particularly of the head and neck region, has 
been linked with a significantly increased risk of de-
veloping salivary gland cancers. There appears to be a 
risk from iodine 131 used in the treatment of thyroid 
disease, as the isotope is also concentrated in the sali-
vary glands. Workers in a variety of industries have 
an increased incidence of salivary gland carcinomas in 
general. These industries include asbestos and rubber 
manufacturing, exposure to metal in the plumbing 
industry and nickel compounds, woodworking in the 
automobile industry and employment in hairdressing 
and beauty shops.1 
A number of viruses have been implicated in the 
pathogenesis of salivary gland tumors. There is a strong 
association between Epstein Barr Virus (EBV) and 
lymphoepithelial carcinomas, but EBV has not been 
shown in ACC or other salivary gland carcinomas.1
Endogenous hormones have been reported in nor-
mal and neoplastic salivary glands, but some of the re-
sults have been conflicting. Estrogen receptors have been 
reported in a minority of cases of ACC, mucoepidermoid 
carcinoma, and salivary duct carcinoma.1 Progesterone 
receptors and androgen receptors were also seen in some 
cases of ACC. These findings raised suspicion that some 
of the salivary gland neoplasms including ACC might be 
hormonally dependent like breast carcinoma.1
Clinical presentation
Parotid ACC typically presents with a slowly enlarging 
mass in the parotid region. Spiro et al found out that 
34.3% to 50.8% were palpated in the tail of the parotid 
gland.23 Pain (7.5%) and facial nerve palsy (3.0%) were 
seldom reported. Most of the previously untreated pa-
tients had been aware of the lesion for less than one year 
and in about 7%, intervals of 5 to 10 years elapsed be-
fore a physician was consulted.23
Presentation with lymph node or distant metastasis 
occurs rarely. At least one case was reported where a 
patient presented with a lymph node metastasis high 
in the jugular chain of nodes, without a palpable ab-
normality of the ipsilateral parotid gland. Distant lung 
metastasis have been reported to occur as the present-
ing finding from occult parotid primary ACC, which 
despite extensive clinical evaluation, only became ap-
parent 1 year after initial diagnosis.24 Bilateral occur-
rence,21 familial cases,21, 22 and presentation in children 
have also reported.25
Recurrence and metastasis
ACC has a significant tendency to recur, to produce me-
tastases (cervical lymph nodes and lungs), and may have 
an aggressive evolution.26 The average recurrence rate 
among several studies is estimated to be around 35%.1,4,5 
Late local recurrence was reported in many cases, up to 
30 years from the initial presentation.4,5,27 Metastases 
tend to be hematogenous rather than lymphatic, with 
a propensity for lung and bone. Distant spread occurs 
in 12% of all patients during the course of ACC. Most 
common sites are cervical lymph nodes (16% of ACC 
Figure 1.  Acinic cell carcinoma, which is encapsulated (arrow), and consists of clusters 
of malignant cells forming acini (left). The malignant cells themselves are pleomorphic 
and have atypical nuclei (hematoxylin and eosin, 40×). (Courtesy of  Dr. H. El Teraifi)
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patients) and the lungs.4,5,23,26,28 Other reported sites 
include the cavernous sinus, spine, sternum, orbit, and 
the liver and skin. Moreover, intracranial extension of 
parotid ACC has been mentioned in the literature.29-33
Pathogenesis and pathology
Relatively large studies to identify the submicroscopic 
changes associated with the development and progres-
sion of salivary gland tumors have recently been con-
ducted. The genetic alterations linked to ACC of the 
parotid gland included alterations at chromosomes 4p, 
5q, 6p, and 17p, suggesting the association of tumor 
suppressor genes with the oncogenesis of these tumors. 
Moreover, deletions of chromosome 6q, loss of Y and 
trisomy 21 have been reported in association with 
ACC.34,35 Further molecular studies indicated that reti-
noblastoma pathways, which are common to most hu-
man tumors, might also be involved in the pathogenesis 
and etiology of ACC.36
Acinic/acinar/acinous cell carcinoma belongs to 
the family of adenocarcinomas. Cancers with some 
similarities include adenoid cystic, muco-epidermoid, 
low-grade adenocarcinomas, and possibly some breast 
cancers. Secretory carcinoma of the breast may be an 
identical entity.3
Histology
Untreated ACCs usually present as solitary, encapsulated, 
soft tumors of a grey-white color (Figure 1). In recurrent 
lesions, the tumor often appears lobulated, the capsule 
may be absent, and areas of necrosis may be evident.23
ACC is histologically defined by serous acinar cell dif-
ferentiation (Figure 2). However, several cell types and 
histomorphologic growth patterns are recognized. These 
include acinar, intercalated ductal, vacuolated, clear, and 
non-specific glandular and solid-lobular, microcystic, 
papillary-cystic, and follicular growth patterns.23,37-43
The majority of tumor cells in ACC were described 
as having many ultrastructural features similar to 
those found in the normal serous acinar cells. These 
cells were round or polygonal with eccentrically placed 
nuclei and inconspicuous nucleoli. The lightly baso-
philic cytoplasm was usually finely or coarsely granu-
lar, but was clear focally in some cases. Occasionally, 
this clear, vacuolated cytoplasmic pattern was evident 
throughout the entire tumor. Numerous intercellular 
microcysts, cysts, crude acini, gland-like areas and 
large papillary cystic spaces have been described in 
some cases, and well developed glandular configura-
tions occur rarely. Regardless of the cell pattern, ap-
propriate sections often revealed microscopic invasion 
of the capsule and even nests of tumor cells outside of 
the capsule.2,23,44 Calcification may be prominent. Drut 
and Gimenez reported ACC of the salivary gland with 
massive deposits of globular amyloid.45
Attempts at histological grading have been contro-
versial and inconsistent. Features that are often associ-
ated with more aggressive tumors include frequent mi-
toses, focal necrosis, neural invasion, pleomorphism, 
infiltration, and stromal hyalinization. Occasional 
cases of dedifferentiation from a low-grade to a high-
grade malignancy have been reported. These tumors 
are characterized by cytological pleomorphism, in-
creased mitotic and proliferation indices and have a 
worse prognosis.1
Diagnosis
The diagnosis of ACCs frequently presents difficul-
ties, owing to its great radiological46,47 and cytological 
similarity with benign tumors and with normal acinar 
component of the salivary gland, respectively. The dif-
ferential diagnosis is considered, fundamentally, with 
clear cell carcinomas, mucoepidermoid carcinomas, 
Warthin’s tumor, and oncocytomas.2,23,44
Fine Needle Aspiration Biopsy (FNAB)
FNAB has been well established in the diagnosis of 
salivary gland lesions as it provides essential informa-
tion on the diagnostic/therapeutic management of 
these tumors; this methodology is highly sensitive in 
its diagnostic efficacy. The cytologic findings in fine-
Figure 2. Acinic cell carcinoma cells growing in a solid pattern. most of the tumor cells 
demonstrate fine serous cytoplasmic granules, resembling the normal serous acinar 
salivary gland cells. Some tumor cells with a clear cytoplasm are also noted (H&E stain, 
original magnification 400×). (Courtesy of Dr. A. Al Mutawa)
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needle aspiration (FNA) biopsies of ACCs are usually 
characterized by acinar differentiated tumor cells and 
by certain cytoarchitectural patterns.46,47 ACC is a com-
mon cause of false negative interpretation owing to the 
conspicuous absence of hallmark morphologic features 
of malignancy such as necrosis, cellular pleomorphism, 
and high mitotic activity. It is frequently mistaken for 
benign salivary gland tumors (e.g. oncocytoma) and 
even non-neoplastic parotid parenchyma.47
Radiological Studies
In addition to FNAC and other ancillary diagnostic 
tests, imaging studies are usually used in the pretreat-
ment assessment and management planning of ACC 
which might include ultrasonography, CT, MRI, and 
nuclear scans. Ultrasonography, which is an easy, non-
invasive, and widely available test method, is useful in 
evaluating tumor size, location, and the nature of the tu-
mor. In addition, it is also used to perform ultrasound-
guided FNA biopsies. A CT scan usually demonstrates 
slight contrast enhancement and may be necessary for 
evaluation of tumor size, extension, relationship to fa-
cial nerve and other structures, and distant metastasis 
(Figure 3).
ACC usually demonstrates a nonspecific signal 
intensity pattern on MRI scan that can occasionally 
be somewhat similar to the signal produced by some 
benign salivary neoplasms. Low T1 and T2 signals 
can be detected on some images. The signals correlate 
with the histology, suggesting vascularity, haemosid-
erin deposition, fibrosis and calcification within the 
tumor itself.48,49
Management
In general, management of ACC consists of complete 
surgical removal of the tumor, by total or subtotal pa-
rotidectomy. Postoperative radiotherapy may be useful 
for recurrent, undifferentiated cases of ACC, positive 
margins, and advanced tumors with cervical lymph 
node spread.4,5,38,50 A total parotidectomy with removal 
of the facial nerve might be necessary for some of the 
T3 and T4 cases, and neck dissection may also be in-
dicated. Nerve grafting after total nerve resection is 
recommended for a better quality of life.51,52 Cervical 
lymphadenectomy was reported for 12.1% of cases. 
Nodes were confirmed as positive in 36.6% of patients 
who underwent neck dissection.
Incomplete excision is associated with a lower chance 
of survival so if complete and total tumor removal is not 
achievable, radiation should always be considered. Over 
the past three decades, radiation treatment alone, spe-
cifically with fast neutron beam radiation, has shown 
promising and effective results, especially for inoperable 
tumors. That means that it is a viable alternative to sur-
gery, not just a postoperative adjunct.53 North et al con-
cluded that radiotherapy is recommended for all cases 
of salivary gland cancer postoperatively except for those 
tumors staged as T1N0 or T2N0 with low-grade his-
tology, which were excised with negative margins. It is 
the opinion of the Acinic Cell Carcinoma Information 
Centre at this time, that these are reasonable criteria 
and that fast neutron beam radiation should be strongly 
considered either instead of surgery, or post-operatively, 
in all the above described cases.3
Weighing all the pros and cons, the Acinic Cell 
Carcinoma Information Centre currently recommends 
that fast neutrons are the first “treatment of choice” to 
consider in most ACC cases and that this treatment 
provides the best chance for long-term local control of 
disease. This is especially the case for inoperable or un-
resectable tumors, incomplete tumor removal, residual 
disease, and recurrences. Unfortunately, there are a very 
limited number of high energy fast neutron treatment 
centers worldwide, which sometimes provides a logisti-
cal challenge. If fast neutron treatment is not an option 
for the patient, accelerated hyperfractionated dosing of 
conventional beams should be considered. This method 
has also resulted in high rates of long-term loco-region-
al controls in salivary gland cancers.3,54-56
Chemotherapy for ACC has largely been considered 
ineffective, except for pain-relief or partial responses. 
Figure 3. An axial CT-scan image of a solid mass lesion (acinic 
cell carcinoma) within the right parotid gland (Courtesy of Dr. N. 
Al Zaher).
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The use of chemotherapy for malignant salivary gland 
tumors in general remains under evaluation. ACC has 
been considered chemo-resistant, which is likely due to 
the (usually) slow metabolism of this cancer.3
Predictive Factors and Prognosis
ACC of the salivary glands are distinctive neoplasms 
of individually unpredictable behavior. Contrary to the 
widely accepted notion that ACCs can be equated with 
favorable prognostic groups, such as low-grade mucoepi-
dermoid carcinoma or low grade adenocarinomas, recent 
studies are increasingly suggesting that there is a subset 
of ACCs with poor prognosis. Prolonged follow-up data 
are believed necessary to gauge the impact of treatment 
on survival. Aggressive tumors were treated three times 
as frequently with surgery and radiation compared with 
treatment patterns for less aggressive disease.4,5
Muliple recurrences and metastasis to cervical lymph 
nodes indicate a poor prognosis. Distant metastasis is 
associated with very poor survival. While tumors in the 
submandibular gland are more aggressive than those in 
the parotid gland, ACCs in minor salivary glands are 
less aggressive than those in the major salivary glands.1
The overall 5-year disease-specific survival is estimat-
ed to be around 91%, and 88% at 10 years. Significant 
association was noted between poor survival and high-
grade disease, regional or distant metastasis at presen-
tation, submandibular tumors, pain, male gender, and 
age older than 30 years.57 Short duration of symptoms, 
incomplete excision, frequent mitoses, focal necrosis, 
pleomorphism, neural invasion, infiltration, stromal 
hyalinization, large size and involvement of the deep 
lobe of the parotid gland have also been reported as 
poor prognostic factors.58 In other studies, the presence 
of a predominately solid architecture was strongly asso-
ciated with a poor outcome.49,59 For high-grade tumors, 
the 5-year survival rate was only 33%.6
Surveillance
Although indolent in nature (slow-growing), ACCs are 
quite persistent in their potential for local recurrences 
and distant metastases, often many years later. Local 
and multiple recurrences may occur in up to half of pa-
tients. Recurrences and metastases after 3 to 10 years 
are common, especially after inadequate primary tumor 
removal. Recurrences more than 20 or 30 years after 
initial treatment are also noted in the literature.3 Due 
to the notably high tendency of ACC to recur and to 
produce latent metastasis, long-term follow-up is man-
datory after treatment.4-6,26, 27
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